[1] Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet 2015; 386(10003):1546–55.
[2] Cornberg M, Protzer U, Petersen J, et al. Prophylaxis, diagnosis and therapy of hepatitis B virus infection the German guideline. Z Gastroenterol 2011; 49(7):871–930.
[3] Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taomina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49(4):652–7.
[4] Brechot C, Thiers V, Kremsdorf D, et al. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely “occult”? J Hepatol 2001; 34:194–203.
[5] Bonilla GR, Roberts LR. The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. J Hepatol 2005; 42:760–77.
[6] Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65–73.
[7] Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678–86.
[8] Tseng TC, Liu CJ, Yang HC, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. J Hepatol 2013; 57:441–50.
[9] Yuen MF, Wong DK, Fung J, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: Replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008; 135:1192–9.
[10] Wong DK, Tanaka Y, Lai CL, Mizokami M, Fung J, Yuen MF. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J ClinMicrobiol 2007; 45:3942–7.
[11] Wong DK, Kopaniszen M, Seto W, et al. Reduction of hepatitis B core-related antigen by long term nucleoside nucleotide analogue therapy and its correlation with intrahepatic HBV DNA reduction. HepatolInt 2015;9(S1):202.
[12] Wong DK, Seto WK, Cheung KS, et al. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int 2017; 37:995–1001.
[13] Liao H, Liu Y, Li X-d, et al. Correction: Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy. AntivirTher 2019; 24:151–4.
[14] Suzuki F, Miyakoshi H, Kobayashi M, et al. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J Med Virol 2009; 81:27–33.
[15] Testoni B, Lebossé F, Scholtes C, et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol 2019; 70:615–25.
[16] Chen EQ, Feng S, Wang ML, et al. Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B. Sci Rep 2017; 7(1):173.
[17] Kimura T, Rokuhara A, Sakamoto Y, et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J ClinMicrobiol 2002; 40:439–45.
[18] Loggi E, Vukotic R, Conti F, et al. Serum hepatitis B core‐related antigen is an effective tool to categorize patients with HBeAg‐negative chronic hepatitis B. J Viral Hepat 2019;26(5):568–75.
[19] Shimakawa Y, Ndow G, Njie R, et al. Hepatitis B core-related antigen: An alternative to Hepatitis B virus DNA to assess treatment eligibility in Africa. Clin Infect Dis 2019; doi: 10.1093/cid/ciz412.
[20] Ning X, Nguyen D, Mentzer L, et al. Secretion of genome-free hepatitis B virus–single strand blocking model for virion morphogenesis of para-retrovirus. PLoSPathog. 2011; 7(9):e1002255.
[21] Kimura T, Ohno N, Terada N, et al. Hepatitis B Virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain. J Biol Chem. 2005; 280(23):21713–9.
[22] Testoni B, Lebossé F, Scholtes C, et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol 2019; 70:615–25.
[23] Rokuhara A, Tanaka E, Matsumoto A, et al. Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment. J Viral Hepat 2003; 10:324–30.
[24] Rokuhara A, Sun X, Tanaka E, et al. Hepatitis B virus core and core-related antigen quantitation in Chinese patients with chronic genotype B and C hepatitis B virus infection. J GastroenterolHepatol 2005; 20:1726–30.
[25] Maasoumy B, Wiegand SB, Jaroszewicz J, et al. Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. ClinMicrobiol Infect 2015;21:606.e1–10.
[26] Riveiro-Barciela M, Bes M, Rodríguez-Frías F, et al. Serum hepatitis B core related antigen is more accurate than hepatitis B surface antigen to identify inactive carriers, regardless of hepatitis B virus genotype. ClinMicrobiol Infect 2017; 23:860–7.
[27] Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): Explanation and elaboration. PLoS Med 2007; 4:e297.
[28] Chen EQ, Wang ML, Tao YC, et al. Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA. J Viral Hepat 2019; 26(5):586–95.
[29] Seto W-K, Wong D K-H, Fung J, et al. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B ClinMicrobiol Infect 2014;20:1173–80.
[30] Rokuhara A, Sun X, Tanaka E, et al. Hepatitis B virus core and core-related antigen quantitation in Chinese patients with chronic genotype B and C hepatitis B virus infection. J GastroenterolHepatol 2005:20(11):1726–30.
[31] Mak LY, Wong DK, Cheung KS, Seto WK, Lai CL, Yuen MF. Review article: Hepatitis B core-related antigen (HBcrAg): An emerging marker for chronic hepatitis B virus infection. Aliment PharmacolTher 2018; 47:43–54.
[32] Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. Lancet 2018; 392:2313–24.